Bin Xu, Dibisha Roy, Rene Serrette, Ronald Ghossein
{"title":"界定甲状腺乳头状癌的血管侵犯和淋巴侵犯:形态学标准、D2-40/CD31/ERG 免疫组化的实用性以及与临床病理特征的相关性。","authors":"Bin Xu, Dibisha Roy, Rene Serrette, Ronald Ghossein","doi":"10.1111/his.15285","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>While CAP and ICCR protocols mandate the separation of angioinvasion (AI) and lymphatic invasion (LI) in thyroid carcinoma, distinction between them can be difficult. Because the presence of AI is used to stratify patients with papillary thyroid carcinoma (PTC), there is a need to accurately diagnose AI and LI.</p>\n </section>\n \n <section>\n \n <h3> Methods and results</h3>\n \n <p>AI and LI were evaluated in 162 cases of PTC (<i>n</i> = 155) and high-grade differentiated thyroid carcinoma, papillary phenotype (HGDTCp, <i>n</i> = seven) using haematoxylin and eosin (H&E), D2-40 and CD31/ERG. In encapsulated carcinomas, vascular invasion (VI) was only of AI nature. Infiltrative carcinomas showed LI (46 of 131, 35%) and AI (19 of 131, 16%). The frequency of nodal metastasis (NM) and large volume of NM was 93 and 85%, respectively, in tumours with LI, and 39 and 26%, respectively, in those without LI. Luminal red blood cells and smooth muscle in the wall of large-calibre vessels were not reliable criteria to exclude LI and were seen in 23 and 6% of LI, respectively. LI was an independent predictor for NM, whereas AI is an independent predictor for distant metastasis at presentation in PTC/HGDTCp.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>VI in encapsulated carcinomas, including follicular variant PTC, is only of AI nature, confirming the position of this variant as a close entity to follicular carcinoma rather than classic PTC, whereas infiltrative PTC/HGDTCp may have LI or, less frequently, AI. As no morphological features reliably distinguish LI from AI, D2-40 and CD31/ERG immunostains should be considered for separating AI from LI when dealing with vascular invasion in an infiltrative PTC.</p>\n </section>\n </div>","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"85 6","pages":"950-958"},"PeriodicalIF":3.9000,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Defining angioinvasion and lymphatic invasion in papillary thyroid carcinoma: morphological criteria, utility of D2-40/CD31/ERG immunohistochemistry and correlation with clinicopathological characteristics\",\"authors\":\"Bin Xu, Dibisha Roy, Rene Serrette, Ronald Ghossein\",\"doi\":\"10.1111/his.15285\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>While CAP and ICCR protocols mandate the separation of angioinvasion (AI) and lymphatic invasion (LI) in thyroid carcinoma, distinction between them can be difficult. Because the presence of AI is used to stratify patients with papillary thyroid carcinoma (PTC), there is a need to accurately diagnose AI and LI.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods and results</h3>\\n \\n <p>AI and LI were evaluated in 162 cases of PTC (<i>n</i> = 155) and high-grade differentiated thyroid carcinoma, papillary phenotype (HGDTCp, <i>n</i> = seven) using haematoxylin and eosin (H&E), D2-40 and CD31/ERG. In encapsulated carcinomas, vascular invasion (VI) was only of AI nature. Infiltrative carcinomas showed LI (46 of 131, 35%) and AI (19 of 131, 16%). The frequency of nodal metastasis (NM) and large volume of NM was 93 and 85%, respectively, in tumours with LI, and 39 and 26%, respectively, in those without LI. Luminal red blood cells and smooth muscle in the wall of large-calibre vessels were not reliable criteria to exclude LI and were seen in 23 and 6% of LI, respectively. LI was an independent predictor for NM, whereas AI is an independent predictor for distant metastasis at presentation in PTC/HGDTCp.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>VI in encapsulated carcinomas, including follicular variant PTC, is only of AI nature, confirming the position of this variant as a close entity to follicular carcinoma rather than classic PTC, whereas infiltrative PTC/HGDTCp may have LI or, less frequently, AI. As no morphological features reliably distinguish LI from AI, D2-40 and CD31/ERG immunostains should be considered for separating AI from LI when dealing with vascular invasion in an infiltrative PTC.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13219,\"journal\":{\"name\":\"Histopathology\",\"volume\":\"85 6\",\"pages\":\"950-958\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Histopathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/his.15285\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Histopathology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/his.15285","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:虽然CAP和ICCR规程要求将甲状腺癌的血管侵犯(AI)和淋巴侵犯(LI)分开,但两者之间的区分却很困难。由于AI的存在可用于对甲状腺乳头状癌(PTC)患者进行分层,因此需要准确诊断AI和LI:使用血红素和伊红(H&E)、D2-40和CD31/ERG对162例PTC(n = 155)和高级别分化甲状腺癌乳头状表型(HGDTCp,n = 7)中的AI和LI进行了评估。在包裹性癌中,血管侵犯(VI)仅具有 AI 性质。浸润性癌表现为LI(131例中有46例,占35%)和AI(131例中有19例,占16%)。结节转移(NM)和大体积 NM 的发生率在有 LI 的肿瘤中分别为 93% 和 85%,在没有 LI 的肿瘤中分别为 39% 和 26%。管腔红细胞和大口径血管壁平滑肌不是排除LI的可靠标准,分别见于23%和6%的LI。LI是NM的独立预测因子,而AI则是PTC/HGDTCp发病时远处转移的独立预测因子:结论:包膜癌(包括滤泡变异型PTC)中的VI仅具有AI性质,这证实了该变异型与滤泡癌而非典型PTC接近,而浸润性PTC/HGDTCp可能具有LI或较少见的AI。由于没有形态学特征能可靠地区分 LI 和 AI,因此在处理浸润性 PTC 的血管侵犯时,应考虑使用 D2-40 和 CD31/ERG 免疫标记来区分 AI 和 LI。
Defining angioinvasion and lymphatic invasion in papillary thyroid carcinoma: morphological criteria, utility of D2-40/CD31/ERG immunohistochemistry and correlation with clinicopathological characteristics
Aims
While CAP and ICCR protocols mandate the separation of angioinvasion (AI) and lymphatic invasion (LI) in thyroid carcinoma, distinction between them can be difficult. Because the presence of AI is used to stratify patients with papillary thyroid carcinoma (PTC), there is a need to accurately diagnose AI and LI.
Methods and results
AI and LI were evaluated in 162 cases of PTC (n = 155) and high-grade differentiated thyroid carcinoma, papillary phenotype (HGDTCp, n = seven) using haematoxylin and eosin (H&E), D2-40 and CD31/ERG. In encapsulated carcinomas, vascular invasion (VI) was only of AI nature. Infiltrative carcinomas showed LI (46 of 131, 35%) and AI (19 of 131, 16%). The frequency of nodal metastasis (NM) and large volume of NM was 93 and 85%, respectively, in tumours with LI, and 39 and 26%, respectively, in those without LI. Luminal red blood cells and smooth muscle in the wall of large-calibre vessels were not reliable criteria to exclude LI and were seen in 23 and 6% of LI, respectively. LI was an independent predictor for NM, whereas AI is an independent predictor for distant metastasis at presentation in PTC/HGDTCp.
Conclusion
VI in encapsulated carcinomas, including follicular variant PTC, is only of AI nature, confirming the position of this variant as a close entity to follicular carcinoma rather than classic PTC, whereas infiltrative PTC/HGDTCp may have LI or, less frequently, AI. As no morphological features reliably distinguish LI from AI, D2-40 and CD31/ERG immunostains should be considered for separating AI from LI when dealing with vascular invasion in an infiltrative PTC.
期刊介绍:
Histopathology is an international journal intended to be of practical value to surgical and diagnostic histopathologists, and to investigators of human disease who employ histopathological methods. Our primary purpose is to publish advances in pathology, in particular those applicable to clinical practice and contributing to the better understanding of human disease.